The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity
for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet
been approved in Japan. The purpose of this trial is to evaluate the clinical efficacy and
safety in Japanese adult subjects with community acquired pneumonia receiving ampicillin
sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.